NOTCH1 inhibition enhances the efficacy of conventional chemotherapeutic agents by targeting head neck cancer stem cell

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhao, Zhi Li ^a   Zhang, Lu ^a   Huang, Cong Fa ^a   Ma, Si Rui ^a   Bu, Lin Lin ^a   Liu, Jian Feng ^a   Yu, Guang Tao ^a   Liu, Bing ^b   Gutkind, J Silvio ^c   Kulkarni, Ashok B ^c   Zhang, Wen Feng ^b   Sun, Zhi Jun ^a,b,c  

^a BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^b WUHAN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

24-DIAMINO-5-PHENYLTHIAZOLE; ANTINEOPLASTIC AGENT; CISPLATIN; DIAMINE; DOCETAXEL; FLUOROURACIL; NOTCH1 PROTEIN, HUMAN; NOTCH1 RECEPTOR; SMALL INTERFERING RNA; TAXOID; THIAZOLE DERIVATIVE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CANCER STEM CELL; CELL SELF-RENEWAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; GENETICS; HEAD AND NECK TUMOR; HUMAN; LYMPH NODE METASTASIS; MOUSE; NUDE MOUSE; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SELF RENEWAL; CISPLATIN; DIAMINES; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; LYMPHATIC METASTASIS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASTIC STEM CELLS; RECEPTOR, NOTCH1; RNA, SMALL INTERFERING; TAXOIDS; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964671849     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep24704     Document Type: Article

References (51)

1. Reya, T., Morrison, S. J., Clarke, M. F. & Weissman, I. L. Stem cells, cancer, and cancer stem cells. Nature 414, 105-111 (2001).
2. Holohan, C., Van Schaeybroeck, S., Longley, D. B. & Johnston, P. G. Cancer drug resistance: an evolving paradigm. Nat Rev Cancer 13, 714-726 (2013).
3. Vermeulen, L., de Sousa e Melo, F., Richel, D. J. & Medema, J. P. The developing cancer stem-cell model: clinical challenges and opportunities. Lancet Oncol 13, e83-89 (2012).
4. Jemal, A. et al. Global cancer statistics. CA Cancer J Clin 61, 69-90 (2011).
5. Haddad, R. I. & Shin, D. M. Recent advances in head and neck cancer. N Engl J Med 359, 1143-1154 (2008).
6. Hunter, K. D., Parkinson, E. K. & Harrison, P. R. Profiling early head and neck cancer. Nat Rev Cancer 5, 127-135 (2005).
7. Prince, M. E. & Ailles, L. E. Cancer stem cells in head and neck squamous cell cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 26, 2871-2875 (2008).
8. Artavanis-Tsakonas, S., Rand, M. D. & Lake, R. J. Notch signaling: cell fate control and signal integration in development. Science 284, 770-776 (1999).
9. Yabuuchi, S. et al. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. Cancer Lett 335, 41-51 (2013).
10. Zhang, J. P. et al. Overexpression of Notch ligand Dll1 in B16 melanoma cells leads to reduced tumor growth due to attenuated vascularization. Cancer Lett 309, 220-227 (2011).
11. Bao, B. et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett 307, 26-36 (2011).
12. Izumchenko, E. et al. Notch1 mutations are drivers of oral tumorigenesis. Cancer Prev Res (Phila) 8, 277-286 (2015).
13. Song, X. et al. Common and complex Notch1 mutations in Chinese oral squamous cell carcinoma. Clin Cancer Res 20, 701-710 (2014).
14. Stransky, N. et al. The mutational landscape of head and neck squamous cell carcinoma. Science 333, 1157-1160 (2011).
15. Agrawal, N. et al. Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science 333, 1154-1157 (2011).
16. Capaccione, K. M. & Pine, S. R. The Notch signaling pathway as a mediator of tumor survival. Carcinogenesis 34, 1420-1430 (2013).
17. Chu, Q., Orr, B. A., Semenkow, S., Bar, E. E. & Eberhart, C. G. Prolonged inhibition of glioblastoma xenograft initiation and clonogenic growth following in vivo Notch blockade. Clin Cancer Res 19, 3224-3233 (2013).
18. Pannuti, A. et al. Targeting Notch to target cancer stem cells. Clin Cancer Res 16, 3141-3152 (2010).
19. Hassan, K. A. et al. Notch pathway activity identifies cells with cancer stem cell-like properties and correlates with worse survival in lung adenocarcinoma. Clin Cancer Res 19, 1972-1980 (2013).
20. Yen, W. C. et al. Targeting notch signaling with a notch2/notch3 antagonist (tarextumab) inhibits tumor growth and decreases tumor-initiating cell frequency. Clin Cancer Res 21, 2084-2095 (2015).
21. Cancer Genome Atlas, N. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 517, 576-582 (2015).
22. Golebiewska, A., Brons, N. H., Bjerkvig, R. & Niclou, S. P. Critical appraisal of the side population assay in stem cell and cancer stem cell research. Cell Stem Cell 8, 136-147 (2011).
23. Peng, C. H. et al. A novel molecular signature identified by systems genetics approach predicts prognosis in oral squamous cell carcinoma. PLos One 6, e23452 (2011).
24. Zhong, L. P. et al. Randomized Phase III Trial of Induction Chemotherapy With Docetaxel, Cisplatin, and Fluorouracil Followed by Surgery Versus Up-Front Surgery in Locally Advanced Resectable Oral Squamous Cell Carcinoma. J Clin Oncol (2012).
25. Prince, M. E. et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci USA 104, 973-978 (2007).
26. Hoey, T. et al. DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency. Cell Stem Cell 5, 168-177 (2009).
27. Pickering, C. R. et al. Integrative genomic characterization of oral squamous cell carcinoma identifies frequent somatic drivers. Cancer Discov 3, 770-781 (2013).
28. Puente, X. S. et al. Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia. Nature 475, 101-105 (2011).
29. de Celis, J. F. & Bray, S. J. The Abruptex domain of Notch regulates negative interactions between Notch, its ligands and Fringe. Development 127, 1291-1302 (2000).
30. Gordon, W. R. et al. Structure of the Notch1-negative regulatory region: implications for normal activation and pathogenic signaling in T-ALL. Blood 113, 4381-4390 (2009).
31. Sun, W. et al. Activation of the NOTCH pathway in head and neck cancer. Cancer Res 74, 1091-1104 (2014).
32. Morohashi, Y. et al. C-terminal fragment of presenilin is the molecular target of a dipeptidic gamma-secretase-specific inhibitor DAPT (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester). J Biol Chem 281, 14670-14676 (2006).
33. Blagosklonny, M. V. Cancer stem cell and cancer stemloids: from biology to therapy. Cancer Biol Ther 6, 1684-1690 (2007).
34. Sun, B. et al. Human umbilical cord blood mesenchymal stem cell-derived extracellular matrix prohibits metastatic cancer cell MDA-MB-231 proliferation. Cancer Lett 296, 178-185 (2010).
35. Bian, Y. et al. Loss of TGF-beta signaling and PTEN promotes head and neck squamous cell carcinoma through cellular senescence evasion and cancer-related inflammation. Oncogene 31, 3322-3332 (2012).
36. Shrivastava, S. et al. Identification of molecular signature of head and neck cancer stem-like cells. Sci Rep 5, 7819 (2015).
37. Ritchie, K. E. & Nor, J. E. Perivascular stem cell niche in head and neck cancer. Cancer Lett 338, 41-46 (2013).
38. Wang, R. et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468, 829-833 (2010).
39. Su, F. et al. Combination therapy of RY10-4 with the gamma-secretase inhibitor DAPT shows promise in treating HER2-amplified breast cancer. Oncotarget (2015).
40. Sun, S. et al. Targeting the c-Met/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res 74, 7546-7559 (2014).
41. Lee, H. E. et al. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. British journal of cancer 104, 1730-1738 (2011).
42. Visvader, J. E. & Lindeman, G. J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nature reviews. Cancer 8, 755-768 (2008).
43. Nor, C. et al. Cisplatin induces Bmi-1 and enhances the stem cell fraction in head and neck cancer. Neoplasia 16, 137-146 (2014).
44. Andersson, E. R. & Lendahl, U. Therapeutic modulation of Notch signalling-are we there yet? Nat Rev Drug Discov 13, 357-378 (2014).
45. Diaz-Padilla, I. et al. A phase Ib combination study of RO4929097, a gamma-secretase inhibitor, and temsirolimus in patients with advanced solid tumors. Invest New Drugs 31, 1182-1191 (2013).
46. Richter, S. et al. A phase I study of the oral gamma secretase inhibitor R04929097 in combination with gemcitabine in patients with advanced solid tumors (PHL-078/CTEP 8575). Invest New Drugs 32, 243-249 (2014).
47. Previs, R. A., Coleman, R. L., Harris, A. L. & Sood, A. K. Molecular pathways: translational and therapeutic implications of the Notch signaling pathway in cancer. Clin Cancer Res 21, 955-961 (2015).
48. Hughes, D. P., Kummar, S. & Lazar, A. J. New, tolerable gamma-secretase inhibitor takes desmoid down a notch. Clin Cancer Res 21, 7-9 (2015).
49. Ma, S. R., Wang, W. M., Huang, C. F., Zhang, W. F. & Sun, Z. J. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition. Oncotarget 6, 8807-8821 (2015).
50. Sun, Z. J. et al. Chemopreventive and chemotherapeutic actions of mTOR inhibitor in genetically defined head and neck squamous cell carcinoma mouse model. Clin Cancer Res 18, 5304-5313 (2012).
51. Goodell, M. A., Brose, K., Paradis, G., Conner, A. S. & Mulligan, R. C. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 183, 1797-1806 (1996).